Compound protein peptide composition and application thereof in improving health of heart and cerebral vessels

Abstract

The invention provides a compound protein peptide composition and application thereof in improving health of heart and cerebral vessels, the compound protein peptide composition comprises earthworm protein peptide, collagen peptide, sea cucumber peptide and other active components, and a multi-target synergistic effect is achieved through a specific ratio and a preparation process. The composition can significantly enhance vascular elasticity, inhibit platelet aggregation and reduce blood viscosity, and is suitable for improving hypertension, hyperlipidemia and microcirculation disturbance. The product can be prepared into tablets, capsules or solid beverages, the uniformity of the tablets is guaranteed by adopting a three-dimensional mixing and segmented tabletting process, the activity of the capsules is maintained through nitrogen-filled sealing of an HPMC shell material, and the palatability of the solid beverages is improved by adding black tea powder and vitamin C. Animal experiments prove that systolic pressure is reduced by 35 mmHg, carotid artery blood flow is improved by 42%, the thrombus dissolution rate reaches 75%, and human body experiments show that the traditional Chinese medicine composition is safe and effective to cardiovascular and cerebrovascular sub-health people.

Description

Technical Field

[0001] This invention relates to the fields of functional foods and preventive medicine, specifically to a complex protein peptide composition and its application in improving cardiovascular health. Background Technology

[0002] Cardiovascular and cerebrovascular diseases are among the major threats to global health. Current health products targeting these diseases often rely on single active ingredients or simple combinations, making it difficult to achieve synergistic regulation of multiple targets. For example, while common soy peptide or plant peptide combinations have some lipid-lowering effects, their overall effects on thrombolysis, microcirculation improvement, and vascular endothelial repair are insufficient. Furthermore, the combination of animal-derived peptides and plant components lacks scientific design, resulting in low bioavailability. Moreover, existing dosage forms do not adequately consider the stability of active peptides in the gastrointestinal environment, affecting actual efficacy.

[0003] Furthermore, the mechanisms of action of peptide compositions in existing technologies are relatively singular, failing to integrate multiple pathways such as thrombolysis, hypotension, anti-inflammation, and metabolic regulation. Some formulations rely excessively on chemical drugs or high-dose single components, which may lead to tolerance with long-term use. Therefore, there is an urgent need to develop a composite formulation that precisely proportions multiple bioactive peptides to synergistically enhance the protective effects on cardiovascular and cerebrovascular systems while ensuring both safety and stability. Summary of the Invention

[0004] The purpose of this section is to outline some aspects of embodiments of the present invention and to briefly describe some preferred embodiments. Simplifications or omissions may be made in this section, as well as in the abstract and title of this application, to avoid obscuring the purpose of these documents; however, such simplifications or omissions should not be construed as limiting the scope of the invention.

[0005] In view of the problems existing in the prior art, the inventors have proposed the present invention.

[0006] Therefore, the purpose of this invention is to overcome the shortcomings of the prior art and provide a composite protein peptide composition and its application in improving cardiovascular and cerebrovascular health.

[0007] To solve the above-mentioned technical problems, the present invention provides the following technical solution: a composite protein peptide composition, comprising the following active ingredients in parts by weight:

[0008] Earthworm protein peptides, 500-700 parts, molecular weight ≤3000 Da, fibrinolytic activity ≥1500 IU / g;

[0009] 40-60 parts of collagen peptides, derived from marine fish collagen, with a molecular weight ≤1000Da;

[0010] Phosphatidylserine 40-60 parts, purity ≥50%;

[0011] Tea leaves contain 20-40 parts of theanine;

[0012] Mussel oligopeptides, 40-60 parts, molecular weight ≤2000Da, TNF-α inhibition rate ≥60%;

[0013] 40-60 portions of oyster peptides, with a zinc content ≥8mg / g;

[0014] 30-50 portions of deer heart blood peptides, derived from artificially bred sika deer, with SOD activity ≥5000U / g;

[0015] Bitter melon peptides, 30-50 parts, have glucose transport promoting activity ≥35%;

[0016] Inulin 100-300 parts, degree of polymerization DP≥23;

[0017] Sea cucumber peptides, 8-12 parts, were prepared by targeted enzymatic hydrolysis with trypsin, with a molecular weight ≤2000 Da and an ACE inhibition rate IC50 ≤0.15 mg / mL;

[0018] 5-15 parts magnesium stearate, 2-5 parts food flavoring.

[0019] As a preferred embodiment of the composite protein peptide composition of the present invention, the earthworm protein peptide retains enzyme activity by freeze-drying, and the directional enzymatic hydrolysis process conditions of the sea cucumber peptide are: trypsin addition of 0.2wt%, 45℃, pH 7.0, and enzymatic hydrolysis for 2 hours.

[0020] In a preferred embodiment of the composite protein peptide composition described in this invention, the mass ratio of each peptide satisfies the following:

[0021] Earthworm protein peptide: sea cucumber peptide = (50-70):1;

[0022] Mussel oligopeptides: Deer heart blood peptides = (1.2-2):1;

[0023] Collagen peptides: bitter melon peptides = (1.2-1.5):1.

[0024] A method for preparing a complex protein peptide composition includes the following steps:

[0025] Raw material pretreatment: Earthworm protein peptides were freeze-dried at -20℃, and sea cucumber peptides were prepared using a directional enzymatic hydrolysis process;

[0026] Segmented blending:

[0027] (a) Earthworm protein peptide, mussel oligopeptide, oyster peptide, deer heart blood peptide and sea cucumber peptide are mixed and mixed in a three-dimensional mixer at 10 r / min for 35 minutes.

[0028] (b) A mixture of collagen peptides, tea theanine, bitter melon peptides, and inulin;

[0029] Overall integration: Add mixtures (a) and (b) to a three-dimensional mixer and mix at 10 rpm for 30 minutes;

[0030] Key component addition: Add phosphatidylserine and mix for 12 minutes;

[0031] Final processing: Add magnesium stearate and food flavoring and mix for 6 minutes;

[0032] Forming: tableting pressure 20±5kN, or capsule filling amount 500mg / capsule.

[0033] As a preferred embodiment of the preparation method of the composite protein peptide composition of the present invention, the three-dimensional mixing environment has a temperature of 25±3℃, a relative humidity of ≤45%, a tablet hardness of 50-60N, and a friability of ≤0.3%.

[0034] As an application of the composite protein peptide composition described in this invention in the preparation of foods or medicines that improve cardiovascular and cerebrovascular health, the application includes: reducing systolic blood pressure by ≥25 mmHg; increasing carotid artery blood flow velocity by ≥40%; and dissolving experimental thrombi with an efficiency of ≥65%.

[0035] As an application of the composite protein peptide composition described in this invention in the preparation of foods or medicines that improve cardiovascular and cerebrovascular health, wherein the composition works synergistically through the following multi-target mechanism:

[0036] Earthworm protein peptides and sea cucumber peptides synergistically enhance ACE inhibition rate to ≥85%;

[0037] Deer heart blood peptides protect t-PA activity, and inulin metabolite butyric acid inhibits PAI-1 expression, together enhancing fibrinolytic activity by ≥40%.

[0038] Collagen peptides provide a matrix for vascular endothelial repair, while oyster peptides activate MMP enzymes.

[0039] A cardiovascular health improvement product, comprising: a complex protein peptide composition, in the form of tablets, capsules or solid beverage; wherein the solid beverage comprises 30-50 parts black tea powder and 20-40 parts vitamin C.

[0040] As a preferred embodiment of the cardiovascular health improvement product of the present invention, the tablets have a dissolution rate of ≥85% in simulated intestinal fluid after 45 minutes and a peptide content retention rate of ≥95% after 6 months of accelerated testing.

[0041] As an application of the composite protein peptide composition prepared by the method of the present invention in inhibiting vascular inflammation, wherein: the composition reduces TNF-α level by ≥60% and whole blood high-shear viscosity by ≥20%.

[0042] The beneficial effects of this invention are as follows: Through the scientific combination of seven animal peptides and functional components, a four-fold synergistic mechanism of "thrombolysis-hypertensive reduction-anti-inflammatory-repair" is achieved. Earthworm protein peptides and sea cucumber peptides synergistically inhibit ACE activity, with an efficiency improvement of more than 40% compared to single components; mussel oligopeptides target and inhibit the inflammatory factor TNF-α, while deer heart blood peptides and inulin indirectly reduce the risk of vascular oxidative damage and endotoxemia through antioxidant and intestinal flora regulation, respectively, forming a multi-dimensional protective network.

[0043] At the formulation level, phosphatidylserine, as an amphiphilic carrier, significantly improves the intestinal absorption rate of peptides, increasing transmembrane transport efficiency by 42-65%; magnesium stearate controls the fractional dissolution of tablets, ensuring targeted release of the active ingredient in the intestine. After 6 months of accelerated testing, the composition retains ≥95% of key activities, and the tablet dissolution meets pharmacopoeia standards, ensuring the long-term stability and clinical efficacy of the product. Detailed Implementation

[0044] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the specific embodiments of the present invention will be described in detail below with reference to the examples in the specification.

[0045] Many specific details are set forth in the following description in order to provide a full understanding of the invention. However, the invention may also be practiced in other ways different from those described herein, and those skilled in the art can make similar extensions without departing from the spirit of the invention. Therefore, the invention is not limited to the specific embodiments disclosed below.

[0046] Secondly, the term "an embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The phrase "in one embodiment" appearing in different places throughout this specification does not necessarily refer to the same embodiment, nor is it a single embodiment or an embodiment selectively excluded from other embodiments.

[0047] Example 1

[0048] This embodiment provides a composite protein peptide composition and its application in improving cardiovascular and cerebrovascular health.

[0049] Specifically, the active ingredients include:

[0050] Earthworm protein peptide 600g (molecular weight 2800±300Da, fibrinolytic activity 1580IU / g);

[0051] 10g of sea cucumber peptides were prepared using a preferred directional enzymatic hydrolysis process: dried sea cucumbers were hydrolyzed with 0.2wt% trypsin at 45℃ and pH 7.0 for 2 hours, followed by ultrafiltration and freeze-drying. The molecular weight was ≤1800Da and the ACE inhibition rate IC50 was 0.12mg / mL.

[0052] Mussel oligopeptides 50g (molecular weight ≤2000Da);

[0053] Deer heart blood peptide 40g (artificially raised sika deer blood source, SOD activity 5500U / g, freeze-dried powder form).

[0054] The excipients are: 10g magnesium stearate (lubricant) and 3g blueberry flavoring (flavor masker).

[0055] As one implementation method, the following steps are performed:

[0056] Segmented blending:

[0057] (a) Protein peptide base mixing: Earthworm protein peptide, mussel oligopeptide, deer heart blood peptide and sea cucumber peptide are put into a three-dimensional mixer (model: VH-10), set the speed to 10 r / min, and mix for 35 minutes.

[0058] (b) Mixing of functional excipients: Add collagen peptides (cod source), tea theanine, bitter melon peptides and inulin to a V-type mixer and mix for 20 minutes;

[0059] Overall integration: Transfer (a) and (b) into a 3D mixer and mix at 10 rpm for 30 minutes;

[0060] Key component addition: Add phosphatidylserine (purity ≥50%), mix for 12 minutes, and utilize its amphiphilicity to improve the dispersibility of the system;

[0061] Final treatment: Add magnesium stearate and blueberry flavoring, mix for 6 minutes;

[0062] Tableting: A rotary tablet press (model: ZP-9) is used, with a pressure of 20±2kN, a tablet weight of 1.05g / tablet, a hardness control of 55±5N, and a brittleness of ≤0.3%.

[0063] Quality and stability verification:

[0064] Dissolution performance: ≤15% release in simulated gastric juice (pH 1.2) after 2 hours, and ≥88% release in simulated intestinal juice (pH 6.8) after 45 minutes, meeting the requirements for intestinal targeted release;

[0065] Accelerated stability: After 6 months at 40℃ / 75%RH, the peptide content retention rate was 96.2% and the ACE inhibitory activity retention rate was 95.1%, confirming the protective effect of phosphatidylserine on the active ingredients in the formulation.

[0066] Example 2

[0067] This embodiment provides a composite protein peptide composition and its application in improving cardiovascular and cerebrovascular health.

[0068] As a preferred implementation method, for individuals at high risk of thrombosis:

[0069] Earthworm protein peptides increased to 650g (increasing the fibrinolytic enzyme dosage);

[0070] Sea cucumber peptides increased to 12g (enhancing ACE inhibitory activity);

[0071] Add 30g of nattokinase (2000FU / g for further synergistic thrombolytic effect);

[0072] Reduce inulin to 150g (to reduce total carbohydrate load).

[0073] Capsule preparation process:

[0074] The specific steps are as follows:

[0075] The mixed powder is passed through an 80-mesh sieve to ensure flowability;

[0076] A fully automatic capsule filling machine is used to fill No. 0 hydroxypropyl methylcellulose (HPMC) capsule shells;

[0077] Filling amount 500mg / capsule, nitrogen-filled and sealed to isolate oxygen;

[0078] Double aluminum foil packaging (10 pieces per blister pack) to protect from light and moisture.

[0079] Animal experiments were conducted using a spontaneously hypertensive rat (SHR) model.

[0080] Grouping and Dosage (n=50):

[0081] Group A: Physiological saline (negative control);

[0082] Group B: Valsartan 4 mg / kg / day (positive control);

[0083] Group C: Low dose of the capsules of this invention (400 mg / kg / d);

[0084] Group D: High dose of the capsules of this invention (800 mg / kg / d);

[0085] Group E: Commercially available soybean peptide capsules (800mg / kg / d).

[0086] Detection indicators and methods:

[0087] Systolic blood pressure: Measured weekly using a non-invasive coccygeal artery blood pressure monitor;

[0088] Thrombolysis rate: Carotid artery thrombosis model, thrombolysis rate calculated by in vitro weighing method;

[0089] Fibrinolytic activity: Plasma t-PA activity and PAI-1 inhibition rate were measured by ELISA.

[0090] Experimental results

[0091] Group Systolic blood pressure decreased (mmHg) Thrombolysis rate (%) t-PA activity increased (%) Group D (High-dose version of this invention) 35.2±3.1 75.3±7.1 63.8±5.2 Group B (positive drug) 42.5±4.2 53.6±5.1 38.7±4.1 Group E (Commercially available products) 16.8±2.7 37.2±4.6 21.5±3.3

[0092] Conclusion: The thrombolysis rate in the high-dose group was significantly better than that in the positive control group (p<0.05), confirming the synergistic thrombolytic mechanism of peptides;

[0093] t-PA activity was increased by 63.8%.

[0094] Example 3

[0095] This embodiment provides a composite protein peptide composition and its application in improving cardiovascular and cerebrovascular health.

[0096] For the palatability and metabolic needs of middle-aged and elderly people:

[0097] Inulin increased to 300g (prebiotic fiber, promotes the growth of bifidobacteria);

[0098] Add 50g of black tea powder (to improve flavor and provide additional antioxidant benefits from tea polyphenols);

[0099] Add 30g of Vitamin C (to protect peptide activity and delay oxidation);

[0100] Remove magnesium stearate (no tableting required).

[0101] The preparation process, specifically, involves the following steps:

[0102] All raw materials were processed by an air jet mill to a particle size ≤100μm;

[0103] Mix at 12 rpm for 40 minutes using a three-dimensional mixer at a mixing temperature of 25°C.

[0104] Dispense into aluminum foil composite film bags (5g / bag) and heat seal.

[0105] Human application protocol, conducting a 12-week intervention trial:

[0106] Subjects: 60 individuals aged 45-65 years with sub-optimal cardiovascular health were randomly divided into an experimental group (this invention) and a control group (commercially available soybean peptide beverage);

[0107] Inclusion criteria: Meets ≥ 2 of the following criteria:

[0108] Borderline hypertension (130-139 / 85-89 mmHg);

[0109] LDL-C ≥ 3.4 mmol / L or HDL-C ≤ 1.0 mmol / L;

[0110] The nailfold microcirculation score is ≥4 points (normal score ≤2 points).

[0111] Intervention plan: Take 1 sachet twice daily, dissolved in water each time;

[0112] Evaluation indicators: Blood pressure: measured weekly with an electronic blood pressure monitor;

[0113] Blood lipids: LDL-C / HDL-C ratio measured by enzymatic method;

[0114] Microcirculation: Microscopic observation of nailfold capillaries;

[0115] Blood rheology: Measurement of high-shear viscosity of whole blood using a rotational viscometer.

[0116] Results and typical cases

[0117] index Experimental group (12-week change rate %) Control group (%) p-value Decreased systolic blood pressure 14.3±2.8 6.2±1.9 <0.01 LDL-C decreases 18.5±3.6 8.7±2.4 <0.01 Microcirculation integral improvement 42.6±7.8 18.3±5.2 <0.01 Whole blood high-shear viscosity decreased 21.4±4.3 9.5±2.6 <0.01

[0118] Detailed description of typical cases:

[0119] A 58-year-old male had a baseline blood pressure of 142 / 88 mmHg, LDL-C of 4.12 mmol / L, and a microcirculation score of 6.8. After 12 weeks of intervention, his blood pressure decreased to 128 / 81 mmHg (a decrease of 9.9%), LDL-C decreased to 3.28 mmol / L (a decrease of 20.4%), and his microcirculation score decreased to 3.9 (an improvement of 42.6%).

[0120] Mechanism association: Inulin promotes butyrate production (serum butyrate ↑3.1 times) and inhibits PAI-1 expression; deer heart blood peptide enhances SOD activity (serum SOD ↑56.8%) and synergistically improves vascular endothelial function.

[0121] The composite protein peptide composition provided by this invention constructs a multi-layered cardiovascular and cerebrovascular protection network through precise formulation and optimized delivery system of multi-source bioactive peptides. From a molecular mechanism perspective, earthworm protein peptides, as the main carrier of plasmin, can specifically cleave the α-chain of fibrinogen, directly disintegrating the thrombus backbone structure; while the short-chain ACE inhibitory peptides (such as the tripeptide VWY) contained in sea cucumber peptides competitively occupy the hydrophobic pockets of angiotensin-converting enzyme, blocking the conversion of AngI to AngII, thus inhibiting vasoconstriction at its source. It is noteworthy that the synergy between these two peptides is not a simple additive effect—the dipeptide fragments generated from the hydrolysis of earthworm protein peptides can enhance the binding force between sea cucumber peptides and the ACE active site, resulting in a qualitative leap in inhibitory efficiency. This bidirectional synergy of "enzyme hydrolysis-inhibition" fundamentally breaks through the limitations of traditional single-component products that only target a single pathological stage.

[0122] At the level of vascular microenvironment regulation, mussel oligopeptides and deer heart blood peptides form a unique "anti-inflammatory-antioxidant" coupling mechanism. Mussel-like adhesion protein peptides in mussel peptides (such as structures rich in DOPA) can target and bind to inflammatory sites in vascular endothelium, blocking the interaction between TNF-α and its receptor; while the superoxide dismutase (SOD) provided by deer heart blood peptides continuously scavenge free radicals, preventing the overactivation of the NF-κB pathway caused by oxidative stress.

[0123] More importantly, inulin, as a prebiotic fiber, produces butyrate during colonic fermentation, which can activate the GPR109A receptor and downregulate the expression of the liver PAI-1 gene, thereby relieving the inhibitory state of the fibrinolytic system. This indirect regulation of the "gut-vascular axis" organically integrates metabolic regulation and circulatory improvement, reflecting the design concept of systems biology.

[0124] From the validation system of the examples, the spontaneously hypertensive rat (SHR) experiment confirmed the regulatory advantages of the composition on acute pathological indicators (such as thrombolysis rate of 75.3%). The essence lies in the fact that the polypeptide components act simultaneously on the coagulation system (inhibiting FXa), the fibrinolytic system (activating t-PA), and platelet function (reducing P-selectin expression). The 42.6% microcirculation improvement rate in the human trial reflects that after inulin regulates the intestinal flora, endotoxin (LPS)-induced vascular endothelial dysfunction is effectively relieved.

[0125] Most importantly, the phenomenon of "blood pressure decrease accompanied by synchronous improvement of microcirculation" observed in typical cases corroborates the unique mechanism of this invention, which is different from conventional antihypertensive drugs. It not only inhibits and reduces vascular tension through the RAS system, but also optimizes tissue perfusion efficiency from the source of hemodynamics.

[0126] In summary, the technological breakthroughs of this invention are reflected in three dimensions: in terms of component design, a cross-species synergistic model of animal peptides and plant components has been established; in terms of mechanism of action, the spatiotemporal integration of the four pathways of "thrombolysis-hypertensive-anti-inflammatory-repair" has been achieved; and in terms of formulation engineering, a biomimetic delivery system has been innovatively constructed using amphiphilic substances.

[0127] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all such modifications or substitutions should be covered within the scope of the claims of the present invention.

Claims

1. A composite protein peptide composition, characterized in that: It contains the following active ingredients by weight: Earthworm protein peptides, 500-700 parts, molecular weight ≤3000 Da, fibrinolytic activity ≥1500 IU / g; 40-60 parts of collagen peptides, derived from marine fish collagen, with a molecular weight ≤1000Da; Phosphatidylserine 40-60 parts, purity ≥50%; Tea leaves contain 20-40 parts of theanine; Mussel oligopeptides, 40-60 parts, molecular weight ≤2000Da, TNF-α inhibition rate ≥60%; 40-60 portions of oyster peptides, with a zinc content ≥8mg / g; 30-50 portions of deer heart blood peptides, derived from artificially bred sika deer, with SOD activity ≥5000U / g; Bitter melon peptides, 30-50 parts, have glucose transport promoting activity ≥35%; Inulin 100-300 parts, degree of polymerization DP≥23; Sea cucumber peptides, 8-12 parts, were prepared by targeted enzymatic hydrolysis with trypsin, with a molecular weight ≤2000 Da and an ACE inhibition rate IC50 ≤0.15 mg / mL; 5-15 parts magnesium stearate, 2-5 parts food flavoring.

2. The composite protein peptide composition according to claim 1, characterized in that: The earthworm protein peptide retains its enzyme activity through freeze-drying. The directional enzymatic hydrolysis process conditions for the sea cucumber peptide are: trypsin addition of 0.2wt%, 45℃, pH 7.0, and enzymatic hydrolysis for 2 hours.

3. The composite protein peptide composition according to claim 1, characterized in that: The mass ratios of each peptide satisfy the following: Earthworm protein peptide: sea cucumber peptide = (50-70):1; Mussel oligopeptides: Deer heart blood peptides = (1.2-2):1; Collagen peptides: bitter melon peptides = (1.2-1.5):

1.

4. A method for preparing a complex protein peptide composition according to any one of claims 1-3, characterized in that: Includes the following steps: Raw material pretreatment: Earthworm protein peptides were freeze-dried at -20℃, and sea cucumber peptides were prepared using a directional enzymatic hydrolysis process; Segmented blending: (a) Earthworm protein peptide, mussel oligopeptide, oyster peptide, deer heart blood peptide and sea cucumber peptide are mixed and mixed in a three-dimensional mixer at 10 r / min for 35 minutes. (b) A mixture of collagen peptides, tea theanine, bitter melon peptides, and inulin; Overall integration: Add mixtures (a) and (b) to a three-dimensional mixer and mix at 10 rpm for 30 minutes; Key component addition: Add phosphatidylserine and mix for 12 minutes; Final processing: Add magnesium stearate and food flavoring and mix for 6 minutes; Forming: tableting pressure 20±5kN, or capsule filling amount 500mg / capsule.

5. The method for preparing a composite protein peptide composition as described in claim 4, characterized in that: The three-dimensional mixing environment has a temperature of 25±3℃, a relative humidity of ≤45%, a tablet hardness of 50-60N, and a friability of ≤0.3%.

6. The use of the complex protein peptide composition according to any one of claims 1-3 in the preparation of foods or medicines that improve cardiovascular and cerebrovascular health, characterized in that, The applications include: reducing systolic blood pressure by ≥25 mmHg; increasing carotid artery blood flow velocity by ≥40%; and dissolving experimental thrombi with an efficiency of ≥65%.

7. The use of the composite protein peptide composition as described in claim 6 in the preparation of foods or medicines that improve cardiovascular and cerebrovascular health, characterized in that: The composition works synergistically through the following multi-target mechanism: Earthworm protein peptides and sea cucumber peptides synergistically enhance ACE inhibition rate to ≥85%; Deer heart blood peptides protect t-PA activity, and inulin metabolite butyric acid inhibits PAI-1 expression, together enhancing fibrinolytic activity by ≥40%. Collagen peptides provide a matrix for vascular endothelial repair, while oyster peptides activate MMP enzymes.

8. A product for improving cardiovascular and cerebrovascular health, characterized in that: The product comprises the complex protein peptide composition according to any one of claims 1-3, and is in the form of tablets, capsules or solid beverages; the solid beverages comprise 30-50 parts of black tea powder and 20-40 parts of vitamin C.

9. A cardiovascular health improvement product as described in claim 8, characterized in that: The tablets showed a dissolution rate of ≥85% in simulated intestinal fluid after 45 minutes, and a peptide content retention rate of ≥95% after 6 months in accelerated testing.

10. The application of the composition prepared by the method of any one of claims 4-5 in inhibiting vascular inflammation, characterized in that: The composition reduces TNF-α levels by ≥60% and whole blood high-shear viscosity by ≥20%.